Journal
NEUROPSYCHOPHARMACOLOGY
Volume 38, Issue 1, Pages 124-137Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/npp.2012.73
Keywords
depression; epigenetics; chromatin; acetylation; methylation; psychiatry
Categories
Funding
- NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH096890] Funding Source: NIH RePORTER
- NIMH NIH HHS [P50 MH096890] Funding Source: Medline
Ask authors/readers for more resources
Major depressive disorder is a chronic, remitting syndrome involving widely distributed circuits in the brain. Stable alterations in gene expression that contribute to structural and functional changes in multiple brain regions are implicated in the heterogeneity and pathogenesis of the illness. Epigenetic events that alter chromatin structure to regulate programs of gene expression have been associated with depression-related behavior, antidepressant action, and resistance to depression or 'resilience' in animal models, with increasing evidence for similar mechanisms occurring in postmortem brains of depressed humans. In this review, we discuss recent advances in our understanding of epigenetic contributions to depression, in particular the role of histone acetylation and methylation, which are revealing novel mechanistic insight into the syndrome that may aid in the development of novel targets for depression treatment. Neuropsychopharmacology Reviews (2013) 38, 124-137; doi:10.1038/npp.2012.73; published online 13 June 2012
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available